| Literature DB >> 35113896 |
Aya Lafta1, Judy Ukrainetz1,2, Sara Davison1, Stephanie Thompson1, Aminu Bello1, Branko Braam1,3.
Abstract
BACKGROUND: Whether fluid overload is associated with vascular stiffness parameters in hemodialysis (HD) patients has not been fully elucidated. We hypothesized that interdialytic fluid accumulation increases vascular stiffness parameters, which improves with intradialytic ultrafiltration.Entities:
Mesh:
Year: 2022 PMID: 35113896 PMCID: PMC8812974 DOI: 10.1371/journal.pone.0262519
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic and clinical characteristics in healthy controls and HD patients.
| Parameters | Healthy controls (n = 26) | HD group (n = 39) | P value | FO HD (n = 20) | non-FO HD (n = 19) | P value |
|---|---|---|---|---|---|---|
| Sex M N, % | 10 (38.4%) | 24 (61.5%) | 0.06 | 14 (70%) | 10 (52.6%) | 0.26 |
| Age, year | 49 (29–56) | 60 (49–66) | 0.006 | 62 (51–68) | 57 (21–67) | 0.05 |
| Body mass index, kg/m2 | 23.9 ± 3.5 | 27.0 ± 5.6 | 0.008 | 26.2 ± 4.9 | 27.9 ± 6.2 | 0.33 |
| Weight, kg | 68.2 ± 10.9 | 78.9 ± 17.4 | 0.003 | 77.9 ± 16.9 | 79.9 ± 18.4 | 0.72 |
| Height, cm | 168.4 ± 6.8 | 170.0 ± 10.7 | 0.50 | 171.2 ± 10.5 | 168.8 ± 11.2 | 0.44 |
| Post-HD weight, kg | - | 77.0 ± 17.7 | - | 75.8 ± 16.9 | 78.2 ± 18.0 | 0.66 |
| Underlying cause of ESRD N, % | ||||||
| Diabetes | ||||||
| Hypertension | ||||||
| Polycystic kidney disease | ||||||
| Glomerulonephritis | ||||||
| Unknown | ||||||
| Other | ||||||
| FO, L | -0.2 ± 0.6 | 2.0 ± 2.4 | <0.0001 | 3.7 ± 2.3 | 0.1 ± 0.5 | < 0.0001 |
| FO post-HD, L | - | 0.0 ± 2.2 | - | 1.6 ± 1.9 | -1.6 ± 1.0 | <0.0001 |
| ECFV, L | 15.10 ± 2.1 | 17.88 ± 4.2 | 0.001 | 19.17± 4.2 | 16.54 ± 3.9 | 0.05 |
| ICFV, L | 19.08 ± 19.0 | 18.30 ± 18.3 | 0.482 | 17.55 ± 4.0 | 19.09 ± 4.7 | 0.28 |
| TBFV, L | 34.18 ± 5.9 | 36.10 ± 8.1 | 0.287 | 36.72 ± 7.9 | 35.63 ± 8.5 | 0.69 |
| FO/ECFV, % | -0.7 (-4.5–3.1) | 7.1 (1.6–19.5) | <0.0001 | 18.8 (10.0–24.9) | 1.6 (-2.0–3.7) | <0.0001 |
| IDWG, kg | - | 1.3 (0.0–3.4) | - | 1.4 (0.87–2.0) | 1.2 (0.6–2.1) | 0.66 |
| Dialysis vintage, years | - | 2.0 (0.1–12.0) | - | 3.0 (2.0–4.0) | 1.0 (0.3–3.0) | 0.02 |
| Net ultrafiltration, L | - | 1.9 ± 1.1 | - | 2.2 ± 1.1 | 1.7 ± 1.0 | 0.19 |
| Anuric N, % | - | 13 (33%) | - | 4 (20%) | 9 (47%) | 0.07 |
| Diabetes N, % | - | 10 (2.5%) | - | 6 (30%) | 4 (21%) | 0.52 |
| Cardiovascular diseases N, % | - | 21 (53%) | - | 10 (50%) | 11(57%) | 0.61 |
| Anti-hypertensive medications N, % | - | 23 (59%) | - | 15 (75%) | 8 (42%) | 0.03 |
| Beta blockers N, % | - | 18 (46%) | - | 14 (70%) | 4 (21%) | 0.25 |
| Calcium channel blockers N, % | - | 11 (28%) | - | 9 (45%) | 3 (15.7% | 0.16 |
| Diuretics N, % | - | 7 (18%) | - | 5 (25%) | 2 (10.5%) | 0.21 |
| Angiotensin receptor blockers N, % | - | 5 (12.8%) | - | 4 (20%) | 1 (5.2%) | 0.40 |
| Baseline systolic blood pressure, mmHg | 117.0 ± 11.9 | 138.2 ± 22.2 | < 0.0001 | 144.4 ± 21.5 | 131.7 ± 21.5 | 0.07 |
| Baseline diastolic blood pressure, mmHg | 69.3 ± 11.3 | 76.1 ± 15.5 | 0.04 | 76.8 ± 11.0 | 75.4 ± 19.5 | 0.78 |
| Baseline mean arterial pressure, mmHg | 85.2 ± 10.8 | 95.7 ± 15.4 | 0.002 | 99.4 ± 13.0 | 91.7 ± 17.2 | 0.12 |
| Baseline heart rate, bpm | 69.6 ± 12.1 | 79.7 ± 12.2 | 0.001 | 78.7 ± 12.2 | 80.8 ± 12.6 | 0.70 |
| Baseline pulse pressure, mmHg | 49.9 ± 9.9 | 61 ± 15.8 | <0.001 | 60.0 ± 11.5 | 50.9 ± 15.3 | 0.04 |
| Baseline PWV, m/s | 8.8 ± 1.4 | 10.3 ± 1.7 | <0.001 | 10.3 ± 1.4 | 10.2 ± 1.9 | 0.83 |
| Baseline AIx, % | -22.3 ± 27.1 | -10.3 ± 36.6 | 0.13 | -14.8 ± 30.7 | -5.5 ± 42.2 | 0.44 |
| 24hr-mean Systolic blood pressure, mmHg | - | 131.6 ± 19.5 | - | 138.2 ± 18.0 | 123.5 ± 17.2 | 0.01 |
| 24hr-mean Diastolic blood pressure, mmHg | - | 70.8 ± 11.5 | - | 72.1 ± 8.8 | 68.8 ± 13.4 | 0.37 |
| 24hr-mean arterial pressure, mmHg | - | 90.4 ± 12.9 | - | 99.4 ± 13.0 | 91.7 ± 17.2 | 0.01 |
| 24hr-mean heart rate, bpm | 78.5 ± 8.6 | 77.8 ± 10.4 | 79.2 ± 6.3 | 0.66 | ||
| 24hr-mean Pulse pressure, mmHg | 60.4 ± 13.4 | - | 65.8 ± 14.4 | 54.7 ± 9.8 | 0.008 | |
| 24hr-mean PWV, m/s | - | 9.9 ± 1.1 | - | 9.9 ± 1.1 | 9.8 ± 1.3 | 0.80 |
| 24hr-mean AIx, % | - | -12.4 ± 22.3 | - | -1.4 ± 21.9 | -25.6 ± 18.1 | <0.001 |
P value < 0.05 is considered significant; ESRD, end stage renal disease; FO, fluid overload; ECFV, extracellular fluid volume; ICFV, intracellular fluid volume; TBFV, total body fluid volume; PWV, pulse wave velocity; AIx, augmentation index; IDWG, intradialytic weight gain. FO post-HD = FO pre-HD- net ultrafiltration.
Predictors of 24-mean AIx in HD patients using univariate and multivariate linear regression analysis.
| Parameters | Univariate analysis | |||
|---|---|---|---|---|
| B | T | CI (95%) | P value | |
| Age, year | 0.112 | 0.066 | -0.453 to 0.676 | 0.69 |
| Pre-HD weight, kg | -0.273 | -1.239 | -0.720 to 0.173 | 0.22 |
| IDWG (kg) | 3.025 | 0.667 | 0.509 to 12.215 | 0.50 |
| FO, L | 5.217 | 3.907 | 2.512 to 7.923 | <0.001 |
| ECFV, L | 0.868 | 0.954 | -0.976 to 0.45 | 0.34 |
| ICFV, L | -0.626 | -0.711 | -2.411 to 1.158 | 0.48 |
| TBFV, L | 0.40 | 0.084 | 0.934 to 1.017 | 0.93 |
| FO / ECFV, % | 1.194 | 4.331 | 0.636 to 1.753 | <0.001 |
| ECFV/TBFV, % | 2.288 | 2.620 | 0.518 to 4.057 | 0.01 |
| ECFV/ICFV, % | 0.594 | 2.685 | 0.146 to 1.042 | 0.01 |
| Systolic blood pressure, mmHg | 0.031 | 0.150 | -0.387 to 0.449 | 0.88 |
| Diastolic blood pressure. mmHg | 0.288 | 0.860 | -0.391 to 0.967 | 0.39 |
| Mean arterial pressure, mmHg | 0.966 | 3.613 | 0.424 to 1.508 | 0.001 |
| Pulse pressure, mmHg | -0.115 | -0.389 | -0.71 to 0.483 | 0.70 |
| Dialysis vintage, years | 1.748 | 1.227 | -1.13 to 4.63 | 0.22 |
| Multivariate analysis | ||||
| FO, L | -0.444 | -0.099 | -9.61 to 8.69 | 0.92 |
| FO / ECFV, % | 1.154 | 1.114 | -0.0094 to 0.032 | 0.27 |
| ECFV/TBFV, % | -3.943 | -0.375 | -25.3 to 17.4 | 0.71 |
| ECFV/ICFV, % | 0.850 | 0.310 | -4.736 to 6.437 | 0.75 |
| Mean arterial pressure, mmHg | 0.656 | 2.380 | 0.095 to 1.217 | 0.02 |
P value < 0.05 is considered significant; IDWG, intradialytic weight gain; FO, fluid overload; ECFV, extracellular fluid volume; ICFV, intracellular fluid volume; TBFV, total body fluid volume.